Nikhil Waingankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nikhil Waingankar has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kutikov
Fox Chase Cancer Center, Philadelphia, USA
6 shared publications Elizabeth Handorf
Fox Chase Cancer Center, Philadelphia, PA
6 shared publicationsMohammed Haseebuddin
Fox Chase Cancer Center, Philadelphia, PA
6 shared publicationsJohn P. Sfakianos
Urology Department, Icahn School of Medicine at Mount Sinai Hospital, New York, NY
5 shared publications- Robert G. Uzzo
Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
5 shared publications - Alberto Martini
Department of Urology University of Cincinnati College of Medicine Cincinnati OH USA
4 shared publications
Latest Publications
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400281
Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma
PURPOSE: Understanding the specific tumor characteristics associated with detectable circulating tumor DNA (ctDNA) in patients with renal cell carcinoma (RCC) is critical for informing future studies aiming to establish the clinical utility of such testing. We characterized the pathologic and clinical features associated with preoperatively detectable ctDNA in patients with renal masses suspicious for RCC. METHODS: Consecutive patients who underwent partial or radical nephrectomy for nonmetastatic suspected RCC (cT1b-T3) during 2022-2023 had prospectively collected tumor-informed ctDNA analyses conducted preoperatively and postoperatively. Descriptive statistics and univariate analyses were used to describe the study findings. RESULTS: Sixty-nine patients with a median age of 62 years (IQR, 51-70) and a median follow-up time of 7 months (IQR, 3-11) had 205 ctDNA samples collected for analysis. Thirty-nine (61%) had preoperative detectable ctDNA of 64 patients. Postoperative ctDNA status was available for 47 patients, and three (6%) had detectable ctDNA. Two had inferior vena cava (IVC) involvement, and one developed metastatic disease. Subgroup analysis of solely malignant RCC (n = 65) revealed that patients with preoperative detectable ctDNA had a higher pathologic stage ( P = .001), larger tumors (7 v 4.5 cm; P = .001), higher tumor complexity ( P = .022), and increased rates of tumor grades 3-4 ( P = .038). All patients with gross renal vein or IVC involvement (n = 9) and those with lymphovascular invasion (n = 6) on pathology had detectable preoperative ctDNA. On univariate analysis, high tumor complexity, larger tumors, and tumor grades 3-4 were found to be predictors of preoperatively detectable ctDNA status. CONCLUSION: Preoperative ctDNA was detectable in 61% of patients with nonmetastatic RCC, and it correlated with clinically relevant features. Clinical trials should consider incorporating both preoperative and postoperative ctDNA analyses to augment prediction of disease recurrence and to refine treatment decision making.
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400281
Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma
PURPOSE: Understanding the specific tumor characteristics associated with detectable circulating tumor DNA (ctDNA) in patients with renal cell carcinoma (RCC) is critical for informing future studies aiming to establish the clinical utility of such testing. We characterized the pathologic and clinical features associated with preoperatively detectable ctDNA in patients with renal masses suspicious for RCC. METHODS: Consecutive patients who underwent partial or radical nephrectomy for nonmetastatic suspected RCC (cT1b-T3) during 2022-2023 had prospectively collected tumor-informed ctDNA analyses conducted preoperatively and postoperatively. Descriptive statistics and univariate analyses were used to describe the study findings. RESULTS: Sixty-nine patients with a median age of 62 years (IQR, 51-70) and a median follow-up time of 7 months (IQR, 3-11) had 205 ctDNA samples collected for analysis. Thirty-nine (61%) had preoperative detectable ctDNA of 64 patients. Postoperative ctDNA status was available for 47 patients, and three (6%) had detectable ctDNA. Two had inferior vena cava (IVC) involvement, and one developed metastatic disease. Subgroup analysis of solely malignant RCC (n = 65) revealed that patients with preoperative detectable ctDNA had a higher pathologic stage ( P = .001), larger tumors (7 v 4.5 cm; P = .001), higher tumor complexity ( P = .022), and increased rates of tumor grades 3-4 ( P = .038). All patients with gross renal vein or IVC involvement (n = 9) and those with lymphovascular invasion (n = 6) on pathology had detectable preoperative ctDNA. On univariate analysis, high tumor complexity, larger tumors, and tumor grades 3-4 were found to be predictors of preoperatively detectable ctDNA status. CONCLUSION: Preoperative ctDNA was detectable in 61% of patients with nonmetastatic RCC, and it correlated with clinically relevant features. Clinical trials should consider incorporating both preoperative and postoperative ctDNA analyses to augment prediction of disease recurrence and to refine treatment decision making.
- 1 February 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (2) , 109-120
Predicting morbidity and mortality after radical cystectomy using risk calculators: A comprehensive review of the literature
- 1 February 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (2) , 109-120
Predicting morbidity and mortality after radical cystectomy using risk calculators: A comprehensive review of the literature
- Open Access
- 12 June 2020
- Published by SAGE Publications in Bladder Cancer
- Vol. 6 (3) , 265-276
Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database
PURPOSE: Data have indicated that residual disease after neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) may be associated with poor outcomes. OBJECTIVE: Analyze differences in overall survival (OS) of patients with residual MIBC treated with NAC + Radical cystectomy (RC), RC alone, or RC + Adjuvant Chemotherapy(AC). MATERIALS AND METHODS: The National Cancer Database was queried for patients who underwent RC alone, NAC + RC, or RC + AC for MIBC stage cT2-4aN0M0 from 2004-2015. Covariates were balanced using propensity score (PS) weighting. Time to death was evaluated from diagnosis. Weighted cox proportional hazards models and Kaplan-Meier survival curves were created to analyze differences in OS. RESULTS: 8,288 patients were included for analysis, 1,899 (23%) received NAC + RC, 5,529 (67%) received RC alone, and 860 (10%) received RC + AC. Patients were sub-stratified based on pathological staging (≤pT2 or >pT2) and compared against treatment with RC alone. In the ≤pT2 cohort, NAC + RC was associated with a decreased risk of death (HR:0.85, 95% CI:0.79–0.91) and RC + AC was associated with an increased risk of death (HR:1.46, 95% CI:1.34–1.60, both p < 0.001) compared to RC alone. In the >pT2 cohort, these associations reversed, with an increased risk of death seen in the NAC + RC group (HR:1.11, 95% CI:1.05–1.18) and a decreased risk of death in the RC + AC group (HR:0.74, 95% CI:0.7–0.77, both p < 0.001). CONCLUSIONS: Patients with >ypT2 disease after NAC experienced a significant increased risk of death when compared to pathological stage-matched patients who underwent RC alone or RC + AC. Biomarkers predictive of NAC resistance may be important to optimize NAC usage and establish treatment algorithms.
- 12 June 2020
- Published by SAGE Publications in Bladder Cancer
- Vol. 6 (3) , 265-276
Open AccessSurvival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database
PURPOSE: Data have indicated that residual disease after neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) may be associated with poor outcomes. OBJECTIVE: Analyze differences in overall survival (OS) of patients with residual MIBC treated with NAC + Radical cystectomy (RC), RC alone, or RC + Adjuvant Chemotherapy(AC). MATERIALS AND METHODS: The National Cancer Database was queried for patients who underwent RC alone, NAC + RC, or RC + AC for MIBC stage cT2-4aN0M0 from 2004-2015. Covariates were balanced using propensity score (PS) weighting. Time to death was evaluated from diagnosis. Weighted cox proportional hazards models and Kaplan-Meier survival curves were created to analyze differences in OS. RESULTS: 8,288 patients were included for analysis, 1,899 (23%) received NAC + RC, 5,529 (67%) received RC alone, and 860 (10%) received RC + AC. Patients were sub-stratified based on pathological staging (≤pT2 or >pT2) and compared against treatment with RC alone. In the ≤pT2 cohort, NAC + RC was associated with a decreased risk of death (HR:0.85, 95% CI:0.79–0.91) and RC + AC was associated with an increased risk of death (HR:1.46, 95% CI:1.34–1.60, both p < 0.001) compared to RC alone. In the >pT2 cohort, these associations reversed, with an increased risk of death seen in the NAC + RC group (HR:1.11, 95% CI:1.05–1.18) and a decreased risk of death in the RC + AC group (HR:0.74, 95% CI:0.7–0.77, both p < 0.001). CONCLUSIONS: Patients with >ypT2 disease after NAC experienced a significant increased risk of death when compared to pathological stage-matched patients who underwent RC alone or RC + AC. Biomarkers predictive of NAC resistance may be important to optimize NAC usage and establish treatment algorithms.
- 1 March 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (3) , 78.e15-78.e21
Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential
- 1 March 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (3) , 78.e15-78.e21
Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential
- 1 September 2019
- Published by Wolters Kluwer Health in Medical Care
- Vol. 57 (9) , 728-733
Trends in Regionalization of Care and Mortality For Patients Treated With Radical Cystectomy
Background: Regionalization to higher volume centers has been proposed as a mechanism to improve short-term outcomes following complex surgery. Objective: The objective of this study was to assess trends in regionalization and mortality for patients undergoing radical cystectomy (RC). Research Design: An observational study of patients receiving RC in the United States from 2004 to 2013. Subjects: Data for patients receiving RC were extracted from the National Cancer Database. Measures: The primary exposure was hospital volume; low-volume hospitals (LVH) included those with PPP=0.02) and 90-day (PP=0.03), whereas rates for HVH remained stable (1.9% vs. 1.4%, P=0.34). Following risk-adjustment, relative to treatment at HVH, treatment at LVH was associated with increased 30-day (hazard ratio: 1.66, 95% CI: 1.53–1.80) and 90-day mortality (hazard ratio: 1.37, 95% confidence interval: 1.30–1.44). Conclusions: Regionalization of RC to HVH was observed from 2004 to 2013. Treatment at LVH was associated with 66% and 33% relative increases in hazard of death at 30 and 90 days, respectively. These findings support the selective referral of complex cases to higher volume centers.
- 1 September 2019
- Published by Wolters Kluwer Health in Medical Care
- Vol. 57 (9) , 728-733
Trends in Regionalization of Care and Mortality For Patients Treated With Radical Cystectomy
Background: Regionalization to higher volume centers has been proposed as a mechanism to improve short-term outcomes following complex surgery. Objective: The objective of this study was to assess trends in regionalization and mortality for patients undergoing radical cystectomy (RC). Research Design: An observational study of patients receiving RC in the United States from 2004 to 2013. Subjects: Data for patients receiving RC were extracted from the National Cancer Database. Measures: The primary exposure was hospital volume; low-volume hospitals (LVH) included those with PPP=0.02) and 90-day (PP=0.03), whereas rates for HVH remained stable (1.9% vs. 1.4%, P=0.34). Following risk-adjustment, relative to treatment at HVH, treatment at LVH was associated with increased 30-day (hazard ratio: 1.66, 95% CI: 1.53–1.80) and 90-day mortality (hazard ratio: 1.37, 95% confidence interval: 1.30–1.44). Conclusions: Regionalization of RC to HVH was observed from 2004 to 2013. Treatment at LVH was associated with 66% and 33% relative increases in hazard of death at 30 and 90 days, respectively. These findings support the selective referral of complex cases to higher volume centers.
- 1 September 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (9) , 572.e21-572.e28
The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
- 1 September 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (9) , 572.e21-572.e28
The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer
Background: Achieving a pathologic complete response (pCR) with neoadjuvant chemotherapy (NAC) in patients with muscle‐invasive bladder cancer (MIBC) has been associated with improved overall survival (OS). This study was aimed at evaluating the impact of pathologic downstaging (pDS; ie, a pT stage at least 1 stage lower than the pre‐NAC cT stage) on the OS of patients with MIBC treated with NAC.Methods: The Retrospective International Study of Cancers of the Urothelial Tract (RISC) and the National Cancer Database (NCDB) were queried for cT2‐4N0M0 patients treated with NAC. A multivariable Cox model including either pDS or pCR was generated. A nested model was built to evaluate the added value of pDS (excluding patients achieving a pCR) to a model including pCR alone. C indices were computed to assess discrimination. NCDB was used for validation. The treatment effect of NAC versus cystectomy alone in achieving pDS was estimated through an inverse probability–weighted regression adjustment.Results: Overall, 189 and 2010 patients from the RISC and NCDB cohorts, respectively, were included; pDS and pCR were achieved by 33% and 35% and by 20% and 15% in RISC and NCDB, respectively. In both data sets, pDS and pCR were associated with better OS and C indices. Adding pDS excluding pCR to the model with pCR fit the data better (likelihood ratio, P = .019 for RISC and P < .001 for NCDB), and it yielded better discrimination (incremental C index, 4.2 for RISC and 1.6 for NCDB). The treatment effect of NAC in achieving pDS was 2.07‐fold (P < .001) in comparison with cystectomy alone.Conclusions: A decrease of at least 1 stage from the cT stage to the pT stage is associated with improved OS in patients with MIBC treated with NAC.
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer
Background: Achieving a pathologic complete response (pCR) with neoadjuvant chemotherapy (NAC) in patients with muscle‐invasive bladder cancer (MIBC) has been associated with improved overall survival (OS). This study was aimed at evaluating the impact of pathologic downstaging (pDS; ie, a pT stage at least 1 stage lower than the pre‐NAC cT stage) on the OS of patients with MIBC treated with NAC.Methods: The Retrospective International Study of Cancers of the Urothelial Tract (RISC) and the National Cancer Database (NCDB) were queried for cT2‐4N0M0 patients treated with NAC. A multivariable Cox model including either pDS or pCR was generated. A nested model was built to evaluate the added value of pDS (excluding patients achieving a pCR) to a model including pCR alone. C indices were computed to assess discrimination. NCDB was used for validation. The treatment effect of NAC versus cystectomy alone in achieving pDS was estimated through an inverse probability–weighted regression adjustment.Results: Overall, 189 and 2010 patients from the RISC and NCDB cohorts, respectively, were included; pDS and pCR were achieved by 33% and 35% and by 20% and 15% in RISC and NCDB, respectively. In both data sets, pDS and pCR were associated with better OS and C indices. Adding pDS excluding pCR to the model with pCR fit the data better (likelihood ratio, P = .019 for RISC and P < .001 for NCDB), and it yielded better discrimination (incremental C index, 4.2 for RISC and 1.6 for NCDB). The treatment effect of NAC in achieving pDS was 2.07‐fold (P < .001) in comparison with cystectomy alone.Conclusions: A decrease of at least 1 stage from the cT stage to the pT stage is associated with improved OS in patients with MIBC treated with NAC.
- 1 May 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (5) , 300.e17-300.e23
Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion
- 1 May 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (5) , 300.e17-300.e23
Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion
- 23 February 2019
- Published by Wiley in BJU International
- Vol. 124 (4) , 665-671
Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma
Objectives To evaluate whether pathological downstaging (pDS) was more informative in predicting overall survival (OS) than pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC). Patients and methods The National Cancer Database was queried for high‐grade cN0M0 patients who had received NAC. pDS was defined as the decrease of at least one stage from cT to pT stage along with pN0, including pCR. A multivariable Cox model predicting OS was generated by fitting alternatively either pDS or pCR and adjusted for potential confounders. The discrimination of the Cox models for predicting OS was evaluated using Harrell's c index. The analyses were repeated in patients diagnosed as cT2‐4N0M0. Results Among 264 patients meeting inclusion criteria, 72 (27%) and 39 (15%) achieved pDS and pCR, respectively. On multivariable analysis, both pDS (HR:0.24; 95%CI:0.13,0.45, pp=0.01) were associated with overall survival. The model including pDS achieved a better discrimination with respect to the model including pCR: c‐index 76.4 vs 72.7, respectively. In the 128 patients diagnosed as cT2‐4, both pDS (HR: 0.19, 95%CI: 0.09,0.40, pp=0.023) were confirmed as predictors of OS. The model including pDS was confirmed to discriminate better than the model including pCR: c‐index 75 vs. 68.9, respectively. Conclusion pDS after NAC for UTUC resulted to be more informative than pCR when predicting OS. These findings, although requiring prospective validation, can aid in the design of clinical trials seeking to refine the use of chemotherapy and other systemic therapies in this setting.
- 23 February 2019
- Published by Wiley in BJU International
- Vol. 124 (4) , 665-671
Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma
Objectives To evaluate whether pathological downstaging (pDS) was more informative in predicting overall survival (OS) than pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy (NAC) for upper tract urothelial carcinoma (UTUC). Patients and methods The National Cancer Database was queried for high‐grade cN0M0 patients who had received NAC. pDS was defined as the decrease of at least one stage from cT to pT stage along with pN0, including pCR. A multivariable Cox model predicting OS was generated by fitting alternatively either pDS or pCR and adjusted for potential confounders. The discrimination of the Cox models for predicting OS was evaluated using Harrell's c index. The analyses were repeated in patients diagnosed as cT2‐4N0M0. Results Among 264 patients meeting inclusion criteria, 72 (27%) and 39 (15%) achieved pDS and pCR, respectively. On multivariable analysis, both pDS (HR:0.24; 95%CI:0.13,0.45, pp=0.01) were associated with overall survival. The model including pDS achieved a better discrimination with respect to the model including pCR: c‐index 76.4 vs 72.7, respectively. In the 128 patients diagnosed as cT2‐4, both pDS (HR: 0.19, 95%CI: 0.09,0.40, pp=0.023) were confirmed as predictors of OS. The model including pDS was confirmed to discriminate better than the model including pCR: c‐index 75 vs. 68.9, respectively. Conclusion pDS after NAC for UTUC resulted to be more informative than pCR when predicting OS. These findings, although requiring prospective validation, can aid in the design of clinical trials seeking to refine the use of chemotherapy and other systemic therapies in this setting.
- 1 February 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (2) , 116-122
A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging
- 1 February 2019
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 37 (2) , 116-122
A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging